• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Quetiapine in Bipolar With OCD

Quetiapine in Bipolar With OCD

January 4, 2022
Richard Moldawsky, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Sahraian A et al, CNS Spectr 2021;1–5


TYPE OF STUDY: Randomized, double-blind, placebo-controlled clinical trial


SSRIs are first-line meds for obsessive-compulsive disorder (OCD), but they may pose risks of mania and rapid cycling when the patient also has bipolar disorder (BD). These conditions overlap more often than expected by chance, but only one controlled trial has looked at how to treat OCD in BD (it was positive and involved topiramate). This eight-week study tested quetiapine for obsessive-compulsive symptoms in patients with stable BD.


Participants had bipolar I with active OCD but were not in a mood episode. All were on lithium and clonazepam and no other psychotropics. Although they had no formal diagnosis of OCD, participants scored as moderate to severe (≥ 17) on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).


In total, 47 adults entered the study after excluding other psychiatric, substance use, and medical diseases. Forty completed the trial, of which half received placebo and half quetiapine. Doses were increased until symptoms resolved or patients couldn’t tolerate more. Patients completed standard clinician-rated scales for OCD (Y-BOCS), mania (Young Mania Rating Scale [YMRS]), and depression (Hamilton Depression Rating Scale [HDRS]) at weeks zero, four, and eight.


The Y-BOCS score was the main outcome measure. On average, it fell by 9.1 in the quetiapine group and 0.3 in the placebo group. Half of the quetiapine group had a significant response (> 34% decrease in Y-BOCS), compared with 5% of the placebo group. Average quetiapine dose was 325 mg, although the dose range wasn’t reported. All patients remained euthymic during the trial based on standard clinician-rated scales (YMRS and HDRS).


Of the 47 study participants, seven dropped out, none for reasons associated with quetiapine. Those on quetiapine were 2.3 times more likely to report side effects (eg, drowsiness, increased appetite, constipation, orthostasis).


TCPR’S TAKE
Although difficult to tolerate, quetiapine may help when OCD is causing significant impairment in patients with BD. It made a difference in this study, bringing Y-BOCS scores from moderate-severe to mild.

General Psychiatry
KEYWORDS antipsychotics bipolar_disorder co-occurring-disorders obsessive-compulsive-disorder ocd quetiapine
    Richard Moldawsky, MD.

    Brexpiprazole Ineffective in Mania

    More from this author
    www.thecarlatreport.com
    Issue Date: January 4, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Working With Severe Personality Disorders
    How to Use SAMe in Clinical Practice
    The New Billing Codes
    Quetiapine in Bipolar With OCD
    CME Post-Test - The Difficult Patient, TCPR, January 2022
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.